Rituximab in the treatment of EBV infection and post-transplantation lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation: a multicenter, prospective, clinical study

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800014960

Enrollment

Unknown

Registered

2018-02-25

Start date

2018-03-01

Completion date

Unknown

Last updated

2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

EBV Infection

Interventions

Case series:Rituximab

Eligibility

Sex/Gender

All

Age

1 Years to 69 Years

Inclusion criteria

Inclusion criteria: 1. Allogeneic hematopoietic stem cell transplantation; 2. Sign informed consent; 3. Aged younger than 70 years old.

Exclusion criteria

Exclusion criteria: 1. Allergic to Rituximab or mouse protein; 2. Severe active bacterial or fungal infection; 3. Infeciton of HIV or active infection of hepatitis B or hepatitis C; 4. Severe cardiac lesion (NYHA IV or left ventricular ejection fraction less than 50%).

Design outcomes

Primary

Measure	Time frame
response;partial response;no response;	—

Countries

China

Contacts

Public ContactJING CHEN

Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine

chenjingscmc@hotmail.com+86-021-38626161-82073

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026